APA (7th ed.) Citation

A, N., DJ, K., L, B., H, S., JO, W., R, K., . . . JS, W. (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology, 7(4), e1316438. https://doi.org/10.1080/2162402X.2017.1316438

Chicago Style (17th ed.) Citation

A, Nelde, et al. "HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination with T-cell-based Immunotherapy." Oncoimmunology 7, no. 4 (2018): e1316438. https://doi.org/10.1080/2162402X.2017.1316438.

MLA (9th ed.) Citation

A, Nelde, et al. "HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination with T-cell-based Immunotherapy." Oncoimmunology, vol. 7, no. 4, 2018, p. e1316438, https://doi.org/10.1080/2162402X.2017.1316438.